LAUSR

1 Pechère M, Opravil M, Wald A et al. Clinical and epidemiologic features of infection with Mycobacterium genavense. Swiss HIV Cohort Study. Arch Intern Med 1995; 155: 400–4. 2 Santos M, Gil-Brusola A, Escandell A et al. Mycobacterium genavense infections in a tertiary hospital and reviewed cases in non-HIV patients. Patholog Res Int 2014; 2014: 371370. 3 Borde JP, Offensperger WB, Kern WV et al. Mycobacterium genavense specific mesenteritic syndrome in HIV-infected patients: a new entity of retractile mesenteritis? AIDS 2013; 27: 2819–22. 4 Esteban J, Garc ıa-Pedrazuela M, Mu~ noz-Egea MC et al. Current treatment of nontuberculous mycobacteriosis: an update. Expert Opin Pharmacother 2012; 13: 967–86. 5 Charles P, Lortholary O, Dechartres A et al. Mycobacterium genavense infections: a retrospective multicenter study in France, 1996-2007. Medicine (Baltimore) 2011; 90: 223–30. 6 Koh WJ, Jeong BH, Jeon K et al. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012; 186: 797–802. 7 Tanaka T, Saito N, Takaki M et al. Refractory chylothorax in HIV/AIDSrelated disseminated mycobacterial infection. Thorax 2016; 71: 960–1. 8 Sekar V, Lavreys L, Van de Casteele T et al. Pharmacokinetics of darunavir/ ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 2010; 54: 4440–5. 9 Dooley KE, Sayre P, Borland J et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013; 62: 21–7. 10 Hicks L, Kant P, Tay PH et al. Visceral leishmaniasis presenting with intestinal failure: a case report and literature review. Eur J Gastroenterol Hepatol 2009; 21: 117–22. J Antimicrob Chemother 2018; 73: 548–549 doi:10.1093/jac/dkx398 Advance Access publication 31 October 2017